JP2018505901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505901A5 JP2018505901A5 JP2017543816A JP2017543816A JP2018505901A5 JP 2018505901 A5 JP2018505901 A5 JP 2018505901A5 JP 2017543816 A JP2017543816 A JP 2017543816A JP 2017543816 A JP2017543816 A JP 2017543816A JP 2018505901 A5 JP2018505901 A5 JP 2018505901A5
- Authority
- JP
- Japan
- Prior art keywords
- daily dose
- day
- schizophrenia
- iloperidone
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 20
- 201000000980 schizophrenia Diseases 0.000 claims description 17
- 229960003162 iloperidone Drugs 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 2
- 238000011418 maintenance treatment Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 description 17
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117173P | 2015-02-17 | 2015-02-17 | |
| US62/117,173 | 2015-02-17 | ||
| US201562172436P | 2015-06-08 | 2015-06-08 | |
| US62/172,436 | 2015-06-08 | ||
| PCT/US2016/018316 WO2016134049A1 (en) | 2015-02-17 | 2016-02-17 | Iloperidone for the treatment of schizophrenia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505901A JP2018505901A (ja) | 2018-03-01 |
| JP2018505901A5 true JP2018505901A5 (enExample) | 2019-03-28 |
| JP6885649B2 JP6885649B2 (ja) | 2021-06-16 |
Family
ID=55532275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543816A Active JP6885649B2 (ja) | 2015-02-17 | 2016-02-17 | 統合失調症の治療のためのイロペリドン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10441580B2 (enExample) |
| EP (1) | EP3258935B1 (enExample) |
| JP (1) | JP6885649B2 (enExample) |
| KR (1) | KR102870956B1 (enExample) |
| CN (2) | CN116211857A (enExample) |
| BR (1) | BR112017017608A2 (enExample) |
| CA (1) | CA2976383C (enExample) |
| ES (1) | ES2870498T3 (enExample) |
| WO (1) | WO2016134049A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
| WO2024137439A1 (en) * | 2022-12-19 | 2024-06-27 | Vanda Pharmaceuticals Inc. | Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia |
| KR20260019503A (ko) | 2023-06-02 | 2026-02-10 | 반다 파마슈티칼즈, 인코퍼레이티드. | 일로페리돈을 사용한 치료 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2398434T3 (es) | 2001-08-31 | 2013-03-19 | Novartis Ag | Isómeros ópticos de un metabolito de iloperidona |
| ES2358416T3 (es) | 2001-10-30 | 2011-05-10 | Novartis Ag | Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella. |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| EP1799865B1 (en) * | 2004-09-30 | 2012-06-06 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| US20100063093A1 (en) | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| JP5535914B2 (ja) * | 2007-09-10 | 2014-07-02 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Ｓｎｐ遺伝子型に基づく抗精神病薬治療 |
| CN101932327A (zh) * | 2007-12-19 | 2010-12-29 | 詹森药业有限公司 | 与长效注射用帕潘立酮酯相关的给药方案 |
| JP2012526562A (ja) * | 2009-05-15 | 2012-11-01 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Ｄｒｄ２又はａｎｋｋ１のｓｎｐ遺伝子型に基づく抗精神病治療 |
| CN104220074A (zh) * | 2011-12-02 | 2014-12-17 | 大日本住友制药株式会社 | 鲁拉西酮新给药方案以及其用于治疗、预防和/或控制至少一种cns病症的用途 |
| CA2865845C (en) | 2012-03-14 | 2020-02-18 | Vanda Pharmaceuticals Inc. | An iloperidone metabolite for use in the treatment of psychiatric disorders |
| PL2887944T3 (pl) * | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
-
2016
- 2016-02-17 CA CA2976383A patent/CA2976383C/en active Active
- 2016-02-17 WO PCT/US2016/018316 patent/WO2016134049A1/en not_active Ceased
- 2016-02-17 EP EP16710038.7A patent/EP3258935B1/en active Active
- 2016-02-17 ES ES16710038T patent/ES2870498T3/es active Active
- 2016-02-17 BR BR112017017608-4A patent/BR112017017608A2/en not_active Application Discontinuation
- 2016-02-17 CN CN202310398029.9A patent/CN116211857A/zh active Pending
- 2016-02-17 KR KR1020177026225A patent/KR102870956B1/ko active Active
- 2016-02-17 JP JP2017543816A patent/JP6885649B2/ja active Active
- 2016-02-17 CN CN201680010479.4A patent/CN107249586A/zh active Pending
- 2016-02-17 US US15/549,820 patent/US10441580B2/en active Active
-
2019
- 2019-09-06 US US16/562,548 patent/US10987346B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012193216A5 (enExample) | ||
| JP2020023574A5 (ja) | 近視予防、治療又は抑制用点眼剤、及び、小胞体ストレス抑制用点眼剤 | |
| JP2015512406A5 (enExample) | ||
| JP2017531033A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2010523587A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| JP2016147915A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| JP2019517542A5 (enExample) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2018529742A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2018529666A5 (enExample) | ||
| JP2014520856A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2017105859A5 (enExample) | ||
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| JP2018521007A5 (enExample) | ||
| JP2014507475A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2019507786A5 (enExample) |